Inactive Instrument

E-Qure Corp.

Equities

EQUR

US26885P1093

Advanced Medical Equipment & Technology

ADB International Group, Inc. Announces Executive Changes

December 27, 2013 at 05:17 pm EST

On December 24, 2013, ADB International Group, Inc.'s board of directors appointed Ron Weissberg as its Chairman, Chief Executive Officer and Chief Financial Officer. Ron Weissberg, age 55. From May 2011 to the present, Mr. Weissberg has been an officer and director of Bio-Light Israeli Life Sciences Investments Ltd. From May 2003 to the present, Mr. Weissberg has been a director of Midroog Ltd. Mr. Yoseph Zekri, formerly Chairman of the company, continues to serves as the company's Secretary and a director.

Effective on December 26, 2013, Mr. Shahar Ginsberg resigned as the company's CEO in order to pursue other business opportunities.

Latest news about E-Qure Corp.

E-Qure Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	22-01-13	CI
E-Qure Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-07-06	CI
E-Qure Corp. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-30	CI
E-Qure Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-13	CI
E-Qure Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-09-17	CI
E-Qure Corp. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-06-25	CI
E-Qure Corp. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-13	CI
E-Qure Corp. Reports Material Updates Regarding Bioelectrical Signal Therapy Device	20-01-21	CI
E-Qure Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-14	CI
E-Qure Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-14	CI
E-Qure Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-16	CI
E-Qure Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2018	19-01-02	CI
E-Qure Corp. Announces Board Appointments	18-07-30	CI
E-Qure To Seek Acquisitions	17-09-07	CI
U.S. FDA Approves Increase in Number of Clinical Sites for E-Qure Corp.'s Pivotal Trial of BST Device for the Treatment of Chronic Wound Care	17-02-23	CI
E-Qure Corp. Signs a Distribution Agreement with Tech - Médica Equipos Médicos S.A.S. in Colombia for its Patented Bio-Electrical Signal Therapy Device	17-01-18	CI
E-QURE Secures Investigational Device Exemption Approval from US Food and Drug Administration to Begin the Clinical Trial of Bio-Electrical Signal Therapy Device	16-11-03	CI
E-Qure Corp. Enters into Distribution Agreement with Chemipal Ltd	15-07-30	CI
E-Qure Corp. Signs First Distribution Agreement with Rubifarm S.A	15-06-10	CI
E-Qure Corp. Auditor Raises 'Going Concern' Doubt	15-05-20	CI
E-Qure Corp. completed the acquisition of Bioelectrical Signal Therapy device assets from Michael Cohen.	14-10-15	CI
E-Qure Corp. agreed to acquire Bioelectrical Signal Therapy device assets from Michael Cohen for $0.35 million.	14-10-10	CI
ADB International Group, Inc. Announces Management Changes	14-08-22	CI
ADB International Group, Inc. Announces Management Changes	14-06-09	CI
ADB International Group, Inc. Announces Executive Changes	13-12-27	CI

Chart E-Qure Corp.

Duration

Period

More charts

Company Profile

E-Qure Corp. is a medical device company that is focused on commercializing its Bioelectrical Signal Therapy Device (BST Device). The BST Device is a non-invasive, painless and easy to use electrotherapy. The Company's non-invasive BST electrical transmission Device mimics the naturally occurring pulses of healing wounds (normal wounds) and creates an electric induction field around the hard-to-heal wound, which accelerates the healing rate. The BST Device stimulates renewed blood flow and oxygen to induce local cell regeneration and therefore promote wound healing. The BST Device is designed to treat chronic wounds, primarily Stage III and Stage IV ulcers. The BST Device is used for the treatment of chronic wounds that include diabetic foot ulcers, vascular (venous or arterial), leg ulcers and pressure (decubitus) ulcers. The BST Device can accelerate healing with rapid wound closure from 45 to 60 days.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
THERMO FISHER SCIENTIFIC	+8.90%	219B
DANAHER CORPORATION	+7.43%	183B
INTUITIVE SURGICAL, INC.	+11.16%	133B
BOSTON SCIENTIFIC CORPORATION	+25.58%	108B
SIEMENS HEALTHINEERS AG	+0.27%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.19%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.96%	48.2B
AGILENT TECHNOLOGIES, INC.	+0.31%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+13.55%	39.35B

Other Advanced Medical Equipment & Technology